The massive overhang of up to 350 million shares (32x current float) creates significant potential selling pressure once the lock-up expires and the registration becomes effective. Monitor for any early sales by non-locked-up holders and for the conversion date on December 2, 2026. The stock's high volatility (6.4% normal daily move) means even moderate selling could cause outsized moves.
Drugs in focus
LSTA drug pipeline →MAR001/005
● Neutral Named in this S-3- Impact
- Phase
- Phase 2b
- Time to market
- At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
- Next catalyst
- None dated
What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 13 $1.21entry
- T+1 · 6d ago −9.92%α −8.01% · $1.09
- T+5 · 2d ago −25.71%α −17.15% · $0.8989
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lisata Therapeutics filed an S-3 shelf registration to register 350,498,987 shares of common stock for resale by selling stockholders. The shares were issued in connection with the September 2026 acquisition of Marea Therapeutics and a concurrent $225 million private placement. The company will not receive any proceeds from the resale, but the registration enables former Marea stockholders and PIPE investors to sell their shares, creating potential overhang.
Key Facts
- S-3 registers 350,498,987 shares for resale by selling stockholders, comprising 1,679,366 Merger Common Shares, 197,951,626 Merger Conversion Shares, and 150,867,995 Private Placement Conversion Shares.
- Shares were issued in the September 2026 acquisition of Marea Therapeutics (stock-for-stock) and a concurrent $225 million PIPE at $1.49137 per share on an as-converted basis.
- As of November 1, 2026, only 10,804,066 shares of common stock were outstanding, so the registered shares represent approximately 32x the current float on a pre-reverse-split basis.
- Conversion of Series C Preferred Stock into common stock is expected on December 2, 2026, subject to stockholder approval and Nasdaq listing approval.
- The company will not receive any proceeds from the resale; proceeds go to selling stockholders.
- Lock-up agreements restrict certain stockholders from selling for 180 days from September 17, 2026, but many selling stockholders are not subject to lock-ups.
Financial Impact
Up to 350.5 million shares registered for resale, representing approximately 32x the current outstanding share count of 10.8 million (pre-reverse-split). At the November 11, 2026 closing price of $1.20, the registered shares have a market value of approximately $420 million.
Risk Factors
- Extreme dilution risk: registered shares are 32x current outstanding shares, creating massive overhang.
- Selling stockholders include major healthcare-focused funds (RA Capital, Perceptive, Third Rock, venBio, Sofinnova, Forbion) that may seek to exit positions.
- The company is a clinical-stage biopharma with no approved products and a going concern risk noted in Marea's audited financial statements.
- Reverse stock split (1-for-5 to 1-for-15) will reduce share count but not the economic dilution from the registered shares.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-043471 |
| Document: ny20085403x1_ex107.htm | 0001140361-26-043471 |
| Document: ny20085403x1_ex5-1.htm | 0001140361-26-043471 |
| Document: ny20085403x1_ex23-2.htm | 0001140361-26-043471 |
| Document: ny20085403x1_ex23-1.htm | 0001140361-26-043471 |
| Document: 0001140361-26-043471-index-headers.html | 0001140361-26-043471 |
| Document: 0001140361-26-043471-index.html | 0001140361-26-043471 |
| Document: 0001140361-26-043471.txt | 0001140361-26-043471 |
Track record
21 reports on LSTA
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
- Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
- Nov 12, 20269d ago S-3 Bearish 6/10 Viewing Entry $1.21 settles Feb 11
- Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
- Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
- Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
- Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers